|
 |
| |
| |
| Licensing & Royalties >> Licensing Opportunities >> Abstract Details |
|
| |
| Latrophilin 3, a Gene Involved in Attention Deficit Hyperactivity Disorder |
Description of Invention:
Attention Deficit Hyperactivity Disorder (ADHD) is the most common behavioral disorder in childhood, and is estimated to affect three to five percent of people in the United States, both children and adults. Treatment typically involves a combination of behavior modification, educational interventions, and medication. There are a variety of medications available for treatment of ADHD; the most frequently prescribed drugs are stimulants or antidepressants. However, currently there is no way to tell in advance which medication will be most helpful for a particular individual.
The inventors have identified haplotypes of latrophilin 3 (LPHN3) that increase susceptibility for development of ADHD. LPHN3 is a G-protein coupled receptor that is specifically expressed in the brain’s mesolimbic system, which is associated with ADHD. The invention describes methods of identifying LPHN3 haplotypes in an individual for determining susceptibility for development of ADHD. Identification of LPHN3 haplotypes in an ADHD-affected individual may also make possible individualized drug treatment plans.
Applications:
- Identify individuals with enhanced susceptibility for ADHD
- Use LPHN3 haplotype information to design individualized treatments
Inventors:
Maximilian Muenke (NHGRI)
Mauricio Arcos-Burgos (NHGRI)
F X Castellanos (NIMH)
Patent Status:
HHS, Reference No. E-312-2006/0
US, , Patent No. 8,003,406, Issued 23 Aug 2011
Licensing Status:
Available for exclusive or nonexclusive licensing.
For Licensing Information Please Contact:
Charlene Sydnor Ph.D.
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325,
Rockville, MD 20852
United States
Email: sydnorc@mail.nih.gov
Phone: 301-435-4689
Fax: 301-402-0220
Ref No: 1504
Updated: 03/2007
|
|
|
|
| |
|
|
|
|